CD274 and head and neck squamous cell carcinoma: Moreover, FDA recommended pembrolizumab in combination with platinum and fluorouracil for patients with advanced HNSCC and in monotherapy for patients whose PD-L1 Combined Positive Score (CPS) expression is ≥ 1% [11].